Global Cisplatin Market Size, Share, and COVID-19 Impact Analysis, By Dosage form (Injections and Others), By Indications (Osteosarcoma Cancer, Breast Cancer, and Testicular Cancer), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Cisplatin Market Insights Forecasts to 2033

• The Global Cisplatin Market Size was estimated at USD 12.33 Billion in 2023
• The Market Size is expected to Grow at a CAGR of around 8.24% from 2023 to 2033
• The Worldwide Cisplatin Market Size is expected to reach USD 27.21 Billion by 2033
• Asia Pacific is predicted to Grow at the fastest CAGR throughout the projection period

The Global Cisplatin Market Size is predicted to exceed USD 27.21 billion by 2033, Growing at a CAGR of 8.24 % from 2023 to 2033. The market growth is facilitated by the rising cases of cancer, technological advancements in cancer treatment, higher investments in the healthcare infrastructure, rising number of FDA approvals, increasing proportion of the geriatric population, and ongoing research on oncological drugs.

Market Overview

The cisplatin market aims to develop, produce, and commercialize the cisplatin drugs that are used in various cancer treatments such as testicular, ovarian, bladder, and lung cancer. Cisplatin is a platinum-based chemotherapeutic medication used to treat a variety of cancers, such as germ cell tumors, sarcomas, carcinomas, and lymphomas. Cisplatin is a class of alkylating agents classified under the antineoplastic or anti-cancer drugs. The FDA-approved drug cisplatin is frequently used off-label for different cancers, including advanced ovarian cancer, testicular cancer, and bladder carcinoma. It works by generating cytotoxicity that is not specific to the cell cycle, which results in strand breakage and intra- and inter-strand crosslinks. Cisplatin is used to treat primary peritoneal cancer and carcinomatosis. It can be given intraperitoneally, intravenously, or intra-arterially. It can be administered as an injection as well. The marketed products of the cisplatin are PLATINEX Injection, Cytoplatin 50, etc.

Several government initiatives are driving market growth. For instance, the Government of India launched the Ayushman Bharat Health and Wellness Centers (AB-HWCs), which aim to service delivery of screening the cancerous conditions along with other non-communicable diseases. Therefore, growing screening activities of cancer in patients escalates the diagnosis and treatment procedures, which results in the expansion of the use of chemotherapeutic drugs like cisplatin, leading to market growth.

The Pradhan Mantri Jan Arogya Yojana, launched by the Government of India, aims to protect cancer patients from catastrophic expenses. It provides health insurance coverage of Rs. 5 lakhs per family per year for secondary or tertiary care hospitalization to over 10.74 crore beneficiaries. The scheme covers chemotherapy, radiotherapy, and surgical oncology in empanelled hospitals, with 435 procedures defined for cancer treatment.

The increasing prevalence of cancer, particularly testicular cancer, accelerates the demand for the cisplatin medications for the management of the cancer, which results in the growth of the cisplatin market. For example, according to the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, Testicular cancer affects 5.9 new cases per 100,000 men annually, with a death rate of 0.3 per 100,000 men. Approximately 0.4% of men will be diagnosed with the disease in their lifetime. In 2021, there were 299,845 men in the United States living with testicular cancer. Contemplating all the optimistic features of the cisplatin drives the market growth, and market growth is anticipated to exceed USD 27.21 billion by 2033.

Report Coverage

This research report categorizes the global cisplatin market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global cisplatin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global cisplatin market.

Driving Factors:

Increasing prevalence of cancer and upsurge in the usage of chemotherapeutics:

The growing incidence of lung, testicular, and ovarian cancers, three of the world's most serious health issues, is propelling the cisplatin market. According to the World Health Organization, factors including an aging population and lifestyle changes are expected to contribute to a substantial rise in the rate of cancer. Cisplatin constitutes a prominent focus in oncology as medical professionals look for efficient treatment choices, propelling the market's expansion. The growing number of cancer patients seeking efficient treatment options is driving up demand for chemotherapy drugs like cisplatin. Cisplatin's use in cancer contexts is further fueled by its broad-spectrum activity and the growth of combination therapy. Established chemotherapeutic treatments are receiving more attention as a result of the global movement toward customized medicine, which supports their ongoing market demand.

Proliferation in the R&D sector and innovations in drug formulations:

Innovations in drug delivery systems and formulations, such as targeted delivery mechanisms and nano-formulations, are propelling the expansion of the cisplatin market. Thus, by lowering side effects and improving the therapeutic index, these technical advancements help patients tolerate treatment better. These enhancements additionally render physicians more inclined to recommend cisplatin, which promotes its consumption. Cisplatin's position in the competitive oncology market is fueled by research into formulations that increase bioavailability and decrease nephrotoxicity. Clinical trials and ongoing research serve as key market drivers, and new treatment paradigms are established by combinatory therapy advancements and research on the effects of cisplatin on various cancer types. New formulations and indications for the use of cisplatin in oncology are the result of R&D efforts fueled by institutional and government funding for cancer research.

Restraining Factors

The side effects associated with the use of cisplatin, such as nephrotoxicity, nausea, high production yield of the generic drugs, stringent regulatory guidelines, high cost of treatment, and prices of the cisplatin medications, may restrict the growth of the market.

Market Segmentation

The global cisplatin market share is classified into dosage form, indications, and distribution channel.

• The injections segment dominated the market with 72.11% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global cisplatin market is categorized into injections and others. Among these, the injections segment dominated the market with 72.11% of the share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segmental expansion is attributed to the greater bioavailability, improved patient compliance, rapid onset of actions, targeted drug delivery, and high effectiveness as it avoids the first pass metabolism, price dosing, greater safety, and adaptability.

• The testicular cancer segment accounted for the largest market share of 34.82% in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global cisplatin market is categorized into osteosarcoma cancer, breast cancer, and testicular cancer. Among these, the testicular cancer segment accounted for the largest market share of 34.82% in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. The segment's growth is facilitated by the increasing prevalence of the cancer, rising cases of the testicular cancer, the effectiveness of cisplatin drug is highly effective in the management of testicular cancer, the capability of cisplatin to interfere with the DNA of the cancer cells, and combined effect of the cisplatin with etoposide gives synergetic effect.

• The hospital pharmacies segment held the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global cisplatin market is categorized as online pharmacies, hospital pharmacies, and retail pharmacies. Among these, the hospital pharmacies segment held the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is attributed to the collaborations of the hospital pharmacies, growing in-patient and out-patient services in hospitals, availability of wide stocks of the anti-cancer medication, cost-effective medications, compounding and dispensing of medicines facilities, and provision of counselling sectors that reduce the risk of the medication error.

Regional Segment Analysis of the Global Cisplatin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global cisplatin market over the predicted timeframe.

North America is anticipated to hold the largest share of the global cisplatin market over the predicted timeframe. This is driven by rising cancer cases and increased research investments in oncology. The adoption of generic formulations has made treatments more accessible, and the use of combination therapies has improved outcomes in advanced cancer cases. Collaborations among pharmaceutical companies have also enhanced drug availability and patient care. The presence of established companies, high cancer prevalence, advanced healthcare infrastructure, and strong R&D investments drive demand for cisplatin in cancer treatment. In the United States, the market focuses on combination therapies and precision medicine to enhance treatment outcomes.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is attributed to factors such as an aging population, a growing middle class, rising cancer awareness, better healthcare access, and investments in healthcare infrastructure. The fastest-growing market is driven by increasing cancer incidence and improving healthcare infrastructure. Generic cisplatin adoption has surged, making it more accessible in developing countries like India and China. Investments in oncology research, awareness campaigns, and regional collaborations among pharmaceutical companies are driving market expansion.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global cisplatin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Cipla
• Metta Lifesciences
• Fortune Healthcare Product Pvt. Ltd.
• Hospira
• Gland Pharma
• Jiangsu Haosen Pharmaceutical
• Athenex Pharmaceutical
• David Bull Laboratories
• Pfizer
• Eli Lilly and Company
• Bedford Pharmaceuticals
• Yunnan Biological Valley Pharmaceutical
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. received Chinese National Medical Products Administration (NMPA) marketing authorization for the programmed cell death ligand 1 (PD-L1)-directed humanized monoclonal antibody Tagitanlimab, which is used in combination with cisplatin and gemcitabine for first-line treatment of recurrent or metastatic nasopharyngeal cancer.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global cisplatin market based on the below-mentioned segments:

Global Cisplatin Market, By Dosage Form

• Injections
• Others

Global Cisplatin Market, By Indications

• Osteosarcoma Cancer
• Breast Cancer
• Testicular Cancer

Global Cisplatin Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Global Cisplatin Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa